Drug Interactions with St. John's Wort

Herbal Supplements: Efficacy, Toxicity, Interactions with Western Drugs, and Effects on Clinical Laboratory Tests

Volumn , Issue , 2010, Pages 273-290

  Krasowski, Matthew D ^a   Blau, John L ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Drug interactions drug interactions with St. John's Wort; Hyperforin role in CYP3A induction by SJW studies, showing CYP3A induction, influenced by hyperforin content; St. John's Wort in treating depression

Indexed keywords

EID: 84886008895     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470910108.ch12     Document Type: Chapter

References (125)

1. Kurth H, Spreemann R. Phytochemical characterization of various St. John's wort extracts. Adv Ther 1998; 15: 117-28.
2. Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008; 4 :CD000448.
3. Kottke MK. Scientifi c and regulatory aspects of nutraceutical products in the United States. Drug Dev Ind Pharm 1998; 24: 1177-95.
4. Gaster B, Holroyd J. St John's wort for depression: a systematic review. Arch Intern Med 2000; 160: 152-6.
5. Bennett DA Jr., Phun L, Polk JF, Voglino SA, Zlotnik V, Raffa RB. Neuropharmacology of St. John's wort (Hypericum). Ann Pharmacother 1998; 32: 1201-8.
6. Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med 2001; 135: 594-600.
7. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data Vital Health Stat (CDC) 2004; 343: 1-20.
8. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report (CDC) 2008; 12: 1-24.
9. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Muller WE. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 1998; 63: 499-510.
10. Nathan P. The experimental and clinical pharmacology of St John's wort (Hypericum perforatum L.). Mol Psychiatry 1999; 4: 333-8.
11. Stahl SM, Grady MM, Moret C, Briley M. SNRIs: their pharmacology, clinical effi cacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005; 10: 732-47.
12. Engel K, Borza S, Philippi E, eds. Red book. Montvale, NJ: Thomson Healthcare, 2008.
13. Choudhuri S, Valerio LG, Jr. Usefulness of studies on the molecular mechanism of action of herbals/botanicals: the case of St. John's wort. J Biochem Mol Toxicol 2005; 19: 1-11.
14. Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338-45.
15. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St. John's wort and cyclosporine. Ann Pharmacother 2000; 34: 1013-6.
16. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J. Drug interaction of St John's wort with cyclosporin. Lancet 2000; 355: 1912.
17. Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J. Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum). Transplantation 2000. 69: 2229-30.
18. Burstein AH, Horton RL, Dunn T, Alfaro RM, Piscitelli SC, Theodore W. Lack of effect of St John's wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000; 68: 605-12.
19. Cheng TO. St John's wort interaction with digoxin. Arch Intern Med 2000; 160: 2548.
20. Karliova M, Treichel U, Malago M, Frilling A, Gerken G, Broelsch CE. Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000; 33: 853-5.
21. Mai I, Kruger H, Budde K, Johne A, Brockmoller J, Neumayer HH, Roots I. Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000; 38: 500-2.
22. Miller JL. Interaction between indinavir and St. John's wort reported. Am J Health Syst Pharm 2000; 57: 625-6.
23. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000; 355: 547-8.
24. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355: 548-9.
25. Ahmed SM, Banner NR, Dubrey SW. Low cyclosporin-A level due to Saint John's wort in heart transplant patients. J Heart Lung Transplant 2001; 20: 795.
26. Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation. Am J Kidney Dis 2001; 38: 1105-7.
27. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995; 104: 1-8.
28. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. The human CYP3A subfamily: practical considerations. Drug Metab Rev 2000; 32: 339-61.
29. Selye H. Resistance to various pesticides induced by catatoxic steroids. Arch Environ Health 1970; 21: 706-10.
30. Selye H. Hormones and resistance. J Pharm Sci 1971; 60: 1-28.
31. Szabo S, Selye H, Kourounakis P, Tache Y. Comparative studies on the effect of adrenocorticotrophic hormone (ACTH) and pregnenolone-16alpha-carbonitrile (PCN) upon drug response and distribution in rats. Biochem Pharmacol 1974; 23: 2083-94.
32. Fouts JR. Factors Affecting hepatic microsomal enzyme systems involved in drug metabolism. Adv Enzyme Regul 1963; 1: 225-33.
33. Kenyon IE. Unplanned pregnancy in an epileptic. Br Med J 1972; 1: 686-7.
34. Dommisse J. Letter: oral contraceptive failure due to drug interaction. S Afr Med J 1976; 50: 796.
35. Skolnick JL, Stoler BS, Katz DB, Anderson WH. Rifampin, oral contraceptives, and pregnancy. JAMA 1976; 236: 1382.
36. Bolt HM, Bolt M, Kappus H. Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocrinol (Copenh) 1977; 85: 189-97.
37. Hillier K. Drug interaction with oral contraceptives. Fertil Contracept 1978; 2: 5-8.
38. Keown PA, Laupacis A, Carruthers G, Stawecki M, Koegler J, McKenzie FN, Wall W, Stiller CR. Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation 1984; 38: 304-6.
39. Van Buren D, Wideman CA, Ried M, Gibbons S, Van Buren CT, Jarowenko M, Flechner SM, Frazier OH, Cooley DA, Kahan BD. The antagonistic effect of rifampin upon cyclosporine bioavailability. Transplant Proc 1984; 16: 1642-5.
40. Howard P, Bixler TJ, Gill B. Cyclosporine-rifampin drug interaction. Drug Intell Clin Pharm 1985; 19: 763-4.
41. Modry DL, Stinson EB, Oyer PE, Jamieson SW, Baldwin JC, Shumway NE. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 1985; 39: 313-4.
42. Schwass DE, Sasaki AW, Houghton DC, Benner KE, Bennett WM. Effect of phenobarbital and cimetidine on experimental cyclosporine nephrotoxicity: preliminary observations. Clin Nephrol 1986; 25 (Suppl 1): S117-20.
43. D'Souza MJ, Pollock SH, Solomon HM. Cyclosporine-phenytoin interaction. Drug Metab Dispos 1988; 16: 256-8.
44. Higgins CF. The multidrug resistance P-glycoprotein. Curr Opin Cell Biol 1993; 5: 684-7.
45. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002; 34: 47-54.
46. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specifi cities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implication for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129-34.
47. Sonoda J, Rosenfeld JM, Xu L, Evans RM, Xie W. A nuclear receptor-mediated xenobiotic response and its implication in drug metabolism and host protection. Curr Drug Metab 2003; 4: 59-72.
48. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276: 14581-7.
49. Lewis DF. 57 Varieties: the human cytochromes P450. Pharmacogenomics 2004; 5: 305-18.
50. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 2005; 45: 477-94.
51. Wolf CR, Smith G. Cytochrome P450 CYP2D6. IARC Sci Publ 1999; 148: 209-29.
52. Dickins M. Induction of cytochromes P450. Curr Top Med Chem 2004; 4: 1745-66.
53. Bolley R, Zulke C, Kammerl M, Fischereder M, Kramer BK. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. Transplantation 2002; 73: 1009.
54. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003; 73: 41-50.
55. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598-604.
56. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000; 66: PL133-9.
57. Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang JS, Chavin KD. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003; 290: 1500-4.
58. Mueller SC, Majcher-Peszynska J, Uehleke B, et al. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006; 62: 29-36.
59. Pal D, Mitra AK. MDR-and CYP3A4-mediated drug-herbal interactions. Life Sci 2006; 78: 2131-45.
60. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St John's wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000; 67: 451-7.
61. Wang LS, Zhou G, Zhu B, et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004; 75: 191-7.
62. Wenk M, Todesco L, Krahenbuhl S. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004; 57: 495-9.
63. Roby CA, Dryer DA, Burstein AH. St. John's wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J Clin Psychopharmacol 2001; 21: 530-2.
64. Mai I, Stormer E, Bauer S, Kruger H, Budde K, Roots I. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003; 18: 819-22.
65. Gómez-Lechón MJ, Donato MT, Castell JV, Jover R. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 2003; 5: 292-312.
66. Komoroski BJ, Zhang S, Cai H, et al. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004; 32: 512-8.
67. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70: 317-26.
68. Wang LS, Zhu B, Abd El-Aty AM, et al. The infl uence of St John's wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 2004; 44: 577-81.
69. Bray BJ, Perry NB, Menkes DB, Rosengren RJ. St. John's wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. Toxicol Sci 2002; 66: 27-33.
70. Hellum BH, Hu Z, Nilsen OG. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin Pharmacol Toxicol 2009; 105: 58-63.
71. Ingelman-Sundberg M, Ronis MJ, Lindros KO, Eliasson E, Zhukov A. Ethanol - inducible cytochrome P4502E1: regulation, enzymology and molecular biology. Alcohol Alcohol Suppl 1994; 2: 131-9.
72. Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K. The recovery time course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol 2008; 65: 701-7.
73. Murakami Y, Tanaka T, Murakami H, Tsujimoto M, Ohtani H, Sawada Y. Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A. Br J Clin Pharmacol 2006; 61: 671-6.
74. Qi JW, Nakamura K, Hosokawa S, Okada Y, Horiuchi R, Yamamoto K. Time - dependent induction of midazolam-1-hydroxylation enzymes in rats treated with St. John's wort. Biol Pharm Bull 2005; 28: 1467-71.
75. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, Berkenstram A. Identifi cation of a human nuclear receptor defi nes a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 1998; 95: 12208-13.
76. Blumberg B, Sabbagh W, Juguilon H, Bolado J, van Meter CM, Ong ES, Evans RM. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 1998; 12: 3195-205.
77. Kliewer SA, Moore JT, Wade L, et al. An orphan nuclear receptor activated by pregnanes defi nes a novel steroid signaling pathway. Cell 1998; 92: 73-82.
78. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998; 102: 1016-23.
79. Gronemeyer H, Laudet V. Transcription factors 3: nuclear receptors. Protein Profi le 1995; 2: 1173-308.
80. Kliewer SA. The nuclear pregnane X receptor regulates xenobiotic detoxifi cation. J Nutr 2003; 133: 2444S-7S.
81. Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002; 23: 687-702.
82. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, Collins JL, Kliewer SA. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97: 7500-2.
83. Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166: R11-6.
84. Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, Davis-Searles PR, Lambert MH, Kliewer SA, Redinbo MR. 2.1 å crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry 2003; 42: 1430-8.
85. Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76: 330-40.
86. Mueller SC, Majcher-Peszynska J, Mundkowski RG, et al. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers. Eur J Clin Pharmacol 2009; 65: 81-87.
87. Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, Sievers H, Frank B, Riethling AK, Drewelow B. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004; 75: 546-57.
88. Will-Shahab L, Bauer S, Kunter U, Roots I, Brattstrom A. St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. Eur J Clin Pharmacol 2009; 65: 287-94.
89. Krasowski MD, Yasuda K, Hagey LR, Schuetz EG. Evolution of the pregnane X receptor: adaptation to cross-species differences in biliary bile salts. Mol Endocrinol 2005; 19: 1720-39.
90. Krasowski MD, Yasuda K, Hagey LR, Schuetz EG. Evolutionary selection across the nuclear hormone receptor superfamily with a focus on the NR1I subfamily (vitamin D, pregnane X, and constitutive androstane receptors). Nucl Recept 2005; 3: 2.
91. Moore LB, Maglich JM, McKee DD, Wisely B, Willson TM, Kliewer SA, Lambert MH, Moore JT. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) defi ne three pharmacologically distinct classes of nuclear receptors. Mol Endocrinol 2002; 16: 977-86.
92. Reschly EJ, Bainy ACD, Mattos JJ, Hagey LR, Bahary N, Mada SR, Ou J, Venkataramanan R, Krasowski MD. Functional evolution of the vitamin D and pregnane X receptors. BMC Evol Biol 2007; 7: 222.
93. Reschly EJ, Krasowski MD. Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab 2006; 7: 349-65.
94. Gerbal-Chaloin S, Daujat M, Pascussi J-M, Pichard-Garcia L, Vilarem M-J, Maurel P. Transcriptional regulation of CYP2C9 gene. J Biol Chem 2002; 277: 209-17.
95. Gerbal-Chaloin S, Pascussi J-M, Pichard-Garcia L, Daujat M, Waechter F, Fabre J-M, Carrère N, Maurel P. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001; 29: 242-51.
96. Gardner-Stephen D, Heydel JM, Goyal A, Lu Y, Xie W, Lindblom T, Mackenzie P, Radominska-Pandya A. Human PXR variants and their differential effects on the regulation of human UDP-glucuronosytransferase gene expression. Drug Metab Dispos 2004; 32: 340-7.
97. Xie W, Yeuh M-F, Radominska-Pandya A, Saini SPS, Negishi Y, Bottroff BS, Cabrera GY, Tukey RH, Evans RM. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci U S A 2003; 100: 4150-5.
98. Schwartz GR. Effect of phenobarbital on jaundice. N Engl J Med 1967; 277: 375.
99. Yaffe SJ, Levy G, Matsuzawa T, Baliah T. Enhancement of glucuronide-conjugating capacity in a hyperbilirubinemic infant due to apparent enzyme induction by phenobarbital. N Engl J Med 1966; 275: 1461-6.
100. Thompson RP, Williams R. Treatment of chronic intrahepatic cholestasis with phenobarbitone. Lancet 1967; 2: 646-8.
101. Hosseinpour F, Ellfolk M, Norlin M, Wikvall K. Phenobarbital suppresses vitamin D3 25-hydroxylase expression: a potential new mechanism for drug-induced osteomalacia. Biochem Biophys Res Commun 2007; 357: 603-7.
102. Pascussi JM, Robert A, Nguyen M, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005; 115: 177-86.
103. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, Kalhorn TF, Watkins PB, Schuetz EG, Thummel KE. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol 2006; 69: 56-65.
104. Bannwarth B. Drug-induced musculoskeletal disorders. Drug Saf 2007; 30: 27-46.
105. Lawson J. Drug-induced metabolic bone disorders. Semin Musculoskelet Radiol 2002; 6: 285-297.
106. Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs 2001; 15: 633-42.
107. Zhai Y, Pai HV, Zhou J, Amico JA, Vollmer RR, Xie W. Activation of pregnane X receptor disrupts glucocorticoid and mineralocorticoid homeostasis. Mol Endocrinol 2007; 21: 138-47.
108. Zhang B, Xie W, Krasowski MD. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 2008; 9: 1695-709.
109. Satia JA, Littman A, Slatore CG, Galanko JA, White E. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. Cancer Epidemiol Biomarkers Prev 2009; 18: 1419-28.
110. Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S, Scholler G, Langheinrich M, Roots I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22: 46-54.
111. Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH, Roots I, Mai I. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol 2003; 55: 203-11.
112. Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003; 74: 525-35.
113. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003; 56: 683-90.
114. Schwarz UI, Büschel B, Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol 2003; 55: 112-3.
115. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71: 414-20.
116. Lee LS, Andrade AS, Flexner C. Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clin Infect Dis 2006; 43: 1052-9.
117. Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 2004; 11: 262-77.
118. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94: 1247-9.
119. Eich-Höchli D, Opplinger R, Golay KP, Baumann P, Eap CB. Methadone maintenance treatment and St. John's wort. Pharmacopsychiatry 2003; 36: 35-7.
120. de Maat MM, Hoetelmans RM, Math t RA, van Gorp EC, Meenhorst PL, Mulder JW, Beijnen JH. Drug interaction between St John's wort and nevirapine. AIDS 2001; 15: 420-1.
121. Eggertsen R, Andreasson A, Andren L. Effects of treatment with a commercially available St John's wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin. Scand J Prim Health Care 2007; 25: 154-9.
122. Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70: 518-24.
123. Hebert MF, Park JM, Chen YL, Akhtar S, Larson AM. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004; 44: 89-94.
124. Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S. Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 2004; 44: 95-101.
125. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57: 592-9.